Aug 16, 2022
Abbott today announced that its FreeStyle Libre 2 flash glucose monitoring system* is now reimbursed under the Régie de l’assurance maladie du Quebec (RAMQ) for Quebec residents aged four and over who manage their diabetes (type 1 or type 2) with multiple daily injections of insulin~.
Jul 26, 2022
Abbott (NYSE: ABT) announces the Health Canada licencing† of NeuroSphere™ Virtual Clinic, a remote programming technology that is the first of its kind in Canada and is compatible with Abbott’s suite of neuromodulation technologies.
Jul 13, 2022
3D CARDIAC MAPPING SYSTEM TO IMPROVE HOW DOCTORS TREAT ABNORMAL HEART RHYTHMS NOW AVAILABLE IN CANADA
Abbott (NYSE: ABT) today announced it has introduced in Canada the EnSite™ X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias. This new platform allows for the creation of a 3D model of the patient's cardiac anatomy in real-time, improving how physicians identify and then treat areas of the heart where abnormal rhythms originate.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.
